Hospital-Acquired Infection Diagnostics Market Thumbnail Image

2022

Hospital-Acquired Infection Diagnostics Market

Hospital-Acquired Infection Diagnostics Market Size, Share, Competitive Landscape and Trend Analysis Report, by Product, By Test Type, By Application, By Infection Type, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2030

LS : Diagnostics and Biotech

Select an option
Author's: Swapna Singh | Roshan Deshmukh
Publish Date:

Get Sample to Email

 

Hospital-Acquired Infection Diagnostics Market Research, 2030

The global hospital-acquired infection diagnostics market was valued at $3.4 billion in 2020, and is projected to reach $7.0 billion by 2030, growing at a CAGR of 7.6% from 2021 to 2030.

Hospital-acquired infections are infections caused by bacterial, viral, or fungal pathogens. In clinical settings, such as a nursing home, rehabilitation center, outpatient clinic, or other therapeutic settings, many infections can be acquired. They can be obtained through an infected patient, the outside environment, or the staff of that facility.  Infections acquired in the hospital are a risk for all patients.

Hospital-Acquired Infection Diagnostics Market, Hospital-Acquired Infection Diagnostics Market size, Hospital-Acquired Infection Diagnostics Market share, Hospital-Acquired Infection Diagnostics Market trends, Hospital-Acquired Infection Diagnostics Market forecast, Hospital-Acquired Infection Diagnostics Market analysis, Hospital-Acquired Infection Diagnostics Market growth, Hospital-Acquired Infection Diagnostics Market opportunity

Hospital acquired infections are more common in people who have had surgery, the elderly, and children. Respiratory infections, surgical-site infections, gastrointestinal infections, urinary tract infections, bloodstream infections, cardiovascular system infections, and bone &joint infections are among the most prevalent infections. Hospital acquired diseases occur worldwide, affecting both developed and developing countries, and are important causes of death among hospitalized patients.

The World Health Organization (WHO) on January 30, 2020 declared COVID-19 as a pandemic and general wellbeing crisis of international concern. COVID-19 has impacted around 210 countries across the globe. Owing to the COVID-19 pandemic, state-run administrations across the globe declared inescapable lockdowns as well as friendly distancing measures to forestall breakdown of the healthcare structure. States have additionally given constraints and preventions on undertakings and elective surgeries. These obstructions continue to influence the growth of different industries, and the enhanced response toward these regulations affects the industry. The distribution, production, and store network have been impacted, due to lockdowns across the globe.

Similarly, the hospital acquired infection diagnostics market had a positive impact during the pandemic, which has attributed to the surge in hospitalized patients and infectious virus contaminating the globe due to which the risk of hospital acquired infections increased. In addition, to accommodate the risk of infections, the demand for hospital acquired infection diagnostics products increased. Hence, overall the pandemic had a positive impact on hospital acquired infections diagnostics market.

The hospital-acquired infection diagnostics market is segmented into Product, Test Type, Application, Infection Type and End User.

The growth of hospital-acquired infection diagnostics market share is driven by surge in the prevalence of hospital acquired infections, increased awareness about hospital acquired infections, improved health care infrastructure, increased R&D spending, technological advancements, and increased government initiatives. However, a key restriction on the global market is lack of awareness regarding hospital acquired diseases in low and middle income nations. The market is primarily driven by rise in incidences of infections caused in clinical settings, especially in developing economies owing to their poor hygiene facilities. However, during hospital-acquired infection diagnostics market forecast the decline in hospital-acquired infections in the developed countries, such as U.S., Germany, and UK impedes the hospital-acquired infection diagnostics market growth.

The hospital-acquired infection diagnostics market size is segmented on the basis of product, test type, application, infection type, end user, and region. By product, the industry is split into instrument &reagents and consumables. By test type, the market is classified into molecular diagnostics, urinalysis, and immunoassay. By application type, the market is fragmented into disease testing and drug resistance testing.

Furthermore, on the basis of infection type, hospital-acquired infection diagnostics market size is classified into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, urinary tract infections (UTI), and others. Its end users include hospitals, clinics, ambulatory surgery centres (ASC), and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Hospital-Acquired Infection Diagnostics Market
By Product
Your browser does not support the canvas element.

Reagents and Consumables segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Product Type Segment Review

By product type, the market is segmented into instrument & reagents and consumables. The reagents segment dominated the market in 2020 with a revenue of $2,093.8 million. Growth of the segment is attributed to low awareness and high prevalence of hospital acquired infections in low and middle income countries.

Hospital-Acquired Infection Diagnostics Market
By Test Type
Your browser does not support the canvas element.

Immunoassay segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Test Type Segment Review

By test type, the market is classified into molecular diagnostics, urinalysis, and immunoassay. The immunoassay segment dominated the market in 2020 with a revenue of $1631.91 million. The growth of the segment can be attributed to surge in infectious diseases, cancer, and sudden outbreak of pandemic.

Hospital-Acquired Infection Diagnostics Market
By Application
Your browser does not support the canvas element.

Drug-Resistance Testing segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Application Type Segment Review

By application type, the market is bifurcated into disease testing and drug resistance testing. The drug-resistance testing segment dominated the market in 2020 with a revenue of $2,667.44 million.

Hospital-Acquired Infection Diagnostics Market
By Infection Type
Your browser does not support the canvas element.

Urinary Tract Infections (UTI) segment is projected as one of the most lucrative segment.

Infection Type Segment Review

By infection type, it is classified into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, urinary tract infections (UTI), and others. The urinary tract segment dominated the market in 2020,with a revenue of  $949.67 million, which is attributed the hospital-acquired infection diagnostics market opportunitydue to high prevalence of pneumonia in hospitalized patients

Hospital-Acquired Infection Diagnostics Market
By End User
Your browser does not support the canvas element.

Hospital segment is projected as one of the most lucrative segment.

End User Type Segment Review

By end user type, it is classified into hospitals, clinics, ambulatory surgery centers (ASC), and others. The hospital segment accounted for the largest segment in 2020, which attributed to the outburst of pandemic and sudden surge of patients.

Hospital-Acquired Infection Diagnostics Market
By Region
2030
North America 
Europe
Asia-Pacific
LAMEA

North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.

Region Type Segment Review

By region, the global hospital acquired infections diagnostics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2020 with a revenue of $1550.81 million, which has attributed to increase in the geriatric population and adoption of advanced diagnostic equipment.

Major key players that operate in the global hospital acquired infection diagnostics market are Abott, Bayer, Becton Dickinson & Company, Danaher Corporation, Ecolab, Hologic, Johnson & Johnson, Merck Kgaa, Pfizer and Steris PLC.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hospital-acquired infection diagnostics market analysis from 2020 to 2030 to identify the prevailing hospital-acquired infection diagnostics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the hospital-acquired infection diagnostics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global hospital-acquired infection diagnostics market trends, key players, market segments, application areas, and market growth strategies.

 

Hospital-Acquired Infection Diagnostics Market Report Highlights

Aspects Details
icon_5
By Product
  • Instrument
  • Reagents and Consumables
icon_6
By Test Type
  • Molecular Diagnostics
  • Immunoassay
  • Others
icon_7
By Application
  • Disease Testing
  • Drug-Resistance Testing
icon_8
By Infection Type
  • Hospital Acquired Pneumonia
  • Bloodstream Infections
  • Surgical Site Infections
  • Gastrointestinal Infections
  • Urinary Tract Infections (UTI)
  • Others
icon_9
By End User
  • Hospital
  • Standalone Laboratories
  • Others
icon_10
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of LAMEA)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
icon_11
Key Market Players

DANAHER CORPORATION, BECTON DICKINSON AND COMPANY, ABBOTT LABORATORIES, MERCK KGaA, STERIS PLC, PFIZER INC., ECOLAB, JOHNSON & JOHNSON, BAYER SCHERING PHARMA LLC, HOLOGIC, INC.

Analyst Review

Infection obtained at a hospital or health care institution by a patient, who was admitted for a reason other than the infection, is called as hospital acquired infection. It is known as nosocomial infection. Infections acquired in the hospital are risk for all patients. Hospital acquired infections are more common in people who have had surgery, the elderly, and children.

Factors such as awareness regarding hospital acquired infections and outburst of global pandemic have gradually increased the demand of HAI diagnostic products thus fueling market's growth. As the geriatric population is more susceptible to diseases, one of the primary drivers that drive the growth of the global hospital-acquired infection diagnostics market is the rise in their population. Owing to change in pathogens and the rise in incidence of hospital-acquired infections, an early diagnosis of an infectious disease is now required. Furthermore, the COVID-19 pandemic has increased the demand for point-of-care immunodiagnostic tests significantly.

In addition, North America accounted for the largest share of the hospital acquired infections diagnostics market, which is attributed to increase in the geriatric population and adoption of advanced diagnostic equipment.

Author Name(s) : Swapna Singh | Roshan Deshmukh
Frequently Asked Questions?

The upcoming trends of Hospital-Acquired Infection Diagnostics Market in the world includes surge in the prevalence of hospital acquired infections, increased awareness about hospital acquired infections, improved health care infrastructure, increased R&D spending, technological advancements, and increased government initiatives

The leading application of Hospital-Acquired Infection Diagnostics Market includes disease testing and drug resistance testing.

North America is the largest regional market for Hospital-Acquired Infection Diagnostics.

Hospital-Acquired Infection Diagnostics expected to reach $6983.75 million by 2030, with a CAGR of 7.6% from 2021 to 2030.

The top companies to hold the market share in Hospital-Acquired Infection Diagnostics includes Abott, Bayer, Becton Dickinson & Company, Danaher Corporation, Ecolab, Hologic, Johnson & Johnson, Merck Kgaa, Pfizer and Steris PLC.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Hospital-Acquired Infection Diagnostics Market

Global Opportunity Analysis and Industry Forecast, 2021-2030